title: Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders.
abstract: Substance use disorders, common in patients with schizophrenia, can lead to poor outcomes. Here we review the literature on the use of antipsychotics in patients with co-occurring schizophrenia and substance use disorder as well as evidence for the use of adjunctive pharmacological treatments targeting substance use in these patients. We also discuss a neurobiological formulation suggesting that the cooccurrence of these disorders may be related to a dysfunction in the dopamine mediated brain reward circuitry. Typical antipsychotics do not appear to decrease substance use in this population. Randomized, controlled trials provide some support for use of the atypical antipsychotic clozapine for co-occurring cannabis use disorder, naltrexone and disulfiram for alcohol use disorder, and also nicotine replacement therapy, sustained-release bupropion and varenicline for tobacco use disorder. Nonetheless, data regarding treatment in patients with these co-occurring disorders are still limited, and many studies reported to date have been either underpowered or did not include a control condition. Further research is needed to evaluate optimal pharmacotherapeutic strategies for this population.
authors.affiliation: Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA.
authors.forename: Sarah C
authors.initials: SC
authors.lastname: Akerman
authors.affiliation: Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA.
authors.forename: Mary F
authors.initials: MF
authors.lastname: Brunette
authors.affiliation: Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA.
authors.forename: Douglas L
authors.initials: DL
authors.lastname: Noordsy
authors.affiliation: Department of Psychiatry, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA.
authors.forename: Alan I
authors.initials: AI
authors.lastname: Green
keywords: Antipsychotic; Brain reward; Clozapine; Schizophrenia; Substance use disorder